HLS Therapeutics (HLS) Scheduled to Post Earnings on Thursday

HLS Therapeutics (TSE:HLS) will post its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect HLS Therapeutics to post earnings of C($0.19) per share for the quarter.

HLS Therapeutics (TSE:HLS) last issued its quarterly earnings data on Thursday, August 8th. The company reported C($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of C($0.25). HLS Therapeutics had a negative return on equity of 24.82% and a negative net margin of 40.90%. The company had revenue of C$19.87 million during the quarter, compared to analysts’ expectations of C$19.25 million.

HLS Therapeutics Price Performance

Shares of HLS traded up C$0.02 during trading hours on Tuesday, hitting C$3.32. The stock had a trading volume of 4,547 shares, compared to its average volume of 26,324. HLS Therapeutics has a 52 week low of C$3.00 and a 52 week high of C$5.48. The stock has a market capitalization of C$105.54 million, a price-to-earnings ratio of -3.27 and a beta of 1.07. The company’s fifty day moving average is C$3.51 and its two-hundred day moving average is C$3.62. The company has a debt-to-equity ratio of 100.44, a current ratio of 2.02 and a quick ratio of 1.01.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus cut their target price on shares of HLS Therapeutics from C$3.75 to C$3.25 in a research note on Tuesday, August 13th.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.